240 related articles for article (PubMed ID: 34589275)
41. Conditional Dicer substrate formation via shape and sequence transduction with small conditional RNAs.
Hochrein LM; Schwarzkopf M; Shahgholi M; Yin P; Pierce NA
J Am Chem Soc; 2013 Nov; 135(46):17322-30. PubMed ID: 24219616
[TBL] [Abstract][Full Text] [Related]
42. Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
Prabhakar N; Zhang J; Desai D; Casals E; Gulin-Sarfraz T; Näreoja T; Westermarck J; Rosenholm JM
Int J Nanomedicine; 2016; 11():6591-6608. PubMed ID: 27994460
[TBL] [Abstract][Full Text] [Related]
43. Targeted delivery of RNAi to cancer cells using RNA-ligand displaying exosome.
Uddin N; Binzel DW; Shu D; Fu TM; Guo P
Acta Pharm Sin B; 2023 Apr; 13(4):1383-1399. PubMed ID: 37139430
[TBL] [Abstract][Full Text] [Related]
44. Re-Engineering RNA Molecules into Therapeutic Agents.
Egli M; Manoharan M
Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
[TBL] [Abstract][Full Text] [Related]
45. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
46. Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Sohrab SS; El-Kafrawy SA; Mirza Z; Kamal MA; Azhar EI
Curr Pharm Des; 2018; 24(1):62-77. PubMed ID: 29119921
[TBL] [Abstract][Full Text] [Related]
47. Dual Tumor-Targeting Nanocarrier System for siRNA Delivery Based on pRNA and Modified Chitosan.
Li L; Hu X; Zhang M; Ma S; Yu F; Zhao S; Liu N; Wang Z; Wang Y; Guan H; Pan X; Gao Y; Zhang Y; Liu Y; Yang Y; Tang X; Li M; Liu C; Li Z; Mei X
Mol Ther Nucleic Acids; 2017 Sep; 8():169-183. PubMed ID: 28918019
[TBL] [Abstract][Full Text] [Related]
48. In Vivo RNAi Efficacy of Palmitic Acid-Conjugated Dicer-Substrate siRNA in a Subcutaneous Tumor Mouse Model.
Kubo T; Yanagihara K; Seyama T
Chem Biol Drug Des; 2016 Jun; 87(6):811-23. PubMed ID: 26800111
[TBL] [Abstract][Full Text] [Related]
49. DICER-LIKE 4 is required for RNA interference and produces the 21-nucleotide small interfering RNA component of the plant cell-to-cell silencing signal.
Dunoyer P; Himber C; Voinnet O
Nat Genet; 2005 Dec; 37(12):1356-60. PubMed ID: 16273107
[TBL] [Abstract][Full Text] [Related]
50. Combination siRNA therapy against feline coronavirus can delay the emergence of antiviral resistance in vitro.
McDonagh P; Sheehy PA; Norris JM
Vet Microbiol; 2015 Mar; 176(1-2):10-8. PubMed ID: 25596968
[TBL] [Abstract][Full Text] [Related]
51. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells.
Liu H; Guo S; Roll R; Li J; Diao Z; Shao N; Riley MR; Cole AM; Robinson JP; Snead NM; Shen G; Guo P
Cancer Biol Ther; 2007 May; 6(5):697-704. PubMed ID: 17426446
[TBL] [Abstract][Full Text] [Related]
52. A tumor-activatable peptide supramolecular nanoplatform for the delivery of dual-gene targeted siRNAs for drug-resistant cancer treatment.
Wu Y; Zhong D; Li Y; Wu H; Zhang H; Mao H; Yang J; Luo K; Gong Q; Gu Z
Nanoscale; 2021 Mar; 13(9):4887-4898. PubMed ID: 33625408
[TBL] [Abstract][Full Text] [Related]
53. Photoinduced RNA interference.
Matsushita-Ishiodori Y; Ohtsuki T
Acc Chem Res; 2012 Jul; 45(7):1039-47. PubMed ID: 22360585
[TBL] [Abstract][Full Text] [Related]
54. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
55. Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice.
Haque F; Xu C; Jasinski DL; Li H; Guo P
Methods Mol Biol; 2017; 1632():359-380. PubMed ID: 28730451
[TBL] [Abstract][Full Text] [Related]
56. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways.
Lee YS; Nakahara K; Pham JW; Kim K; He Z; Sontheimer EJ; Carthew RW
Cell; 2004 Apr; 117(1):69-81. PubMed ID: 15066283
[TBL] [Abstract][Full Text] [Related]
57. Enhancing potency of siRNA targeting fusion genes by optimization outside of target sequence.
Gavrilov K; Seo YE; Tietjen GT; Cui J; Cheng CJ; Saltzman WM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):E6597-605. PubMed ID: 26627251
[TBL] [Abstract][Full Text] [Related]
58. Competition between siRNA duplexes: impact of RNA-induced silencing complex loading efficiency and comparison between conventional-21 bp and Dicer-substrate siRNAs.
Tanudji M; Machalek D; Arndt GM; Rivory L
Oligonucleotides; 2010 Feb; 20(1):27-32. PubMed ID: 19943801
[TBL] [Abstract][Full Text] [Related]
59. The pH-Triggered Triblock Nanocarrier Enabled Highly Efficient siRNA Delivery for Cancer Therapy.
Du L; Zhou J; Meng L; Wang X; Wang C; Huang Y; Zheng S; Deng L; Cao H; Liang Z; Dong A; Cheng Q
Theranostics; 2017; 7(14):3432-3445. PubMed ID: 28912886
[TBL] [Abstract][Full Text] [Related]
60. In vivo application of RNA interference: from functional genomics to therapeutics.
Lu PY; Xie F; Woodle MC
Adv Genet; 2005; 54():117-42. PubMed ID: 16096010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
